Chargement en cours...
Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
BACKGROUND: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated to unde...
Enregistré dans:
| Publié dans: | BMC Pulm Med |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5602932/ https://ncbi.nlm.nih.gov/pubmed/28915874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-017-0468-5 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|